Home » BioMS' MBP8298 Trial Receives Positive Safety Review
BioMS' MBP8298 Trial Receives Positive Safety Review
An independent data safety monitoring board has reviewed data from Canadian drugmaker BioMS Medical’s Phase III trial of MBP8298, a treatment of secondary progressive multiple sclerosis (MS), and recommended continuing the trial.
The randomized, double-blind MAESTRO-03 trial has enrolled approximately 510 patients who will receive either MBP8298 or placebo intravenously every six months for two years.
The primary endpoint is defined as a significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale in patients with HLA-DR2 or HLA-DR4 immune response, BioMS said.
Upcoming Events
-
07May
-
14May
-
30May